ClinicalTrials.gg
CompletedNCT04424927PROACTIVEUpdated Oct 20, 2025Results posted

PRV-015 in Gluten-free Diet Non-responsive Celiac Disease

A Phase 2 interventional study of PRV-015 and Placebo in Celiac Disease, sponsored by Provention Bio, a Sanofi Company. Completed at 38 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Provention Bio, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Enrollment
3rd of 68
388 · median 46
Started
2020
with 6 others
Phase 2
21 of 103
1 open now
Registered
70th of 103
by date

Among the 103 studies in Celiac Disease with a site in United States, this one is the 3rd largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2020, is one of 21 in phase 2, and was the 70th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of PRV-015 in adult patients with non-responsive celiac disease (NRCD) who are on a gluten-free diet (GFD).

Read the detailed description

PRV-015-002b is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 3 dose regimens of PRV-015 in adult patients with NRCD who are on a GFD.

Eligible subjects include male or female adults, 18 to 70 years of age, with a diagnosis of celiac disease and have followed a GFD for at least 12 consecutive months, yet continue to experience symptoms.

Study drug (1 of the 3 doses of PRV-015 or placebo) will be administered in a double-blind fashion, followed by a safety follow-up period.

03

Conditions studied

  • Celiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of celiac disease by intestinal
  • Following a GFD for at least 12 consecutive months
  • Must have detectable (above the lower limit of detection) serum celiac-related antibodies
  • Must have human leukocyte antigen DQ (HLA-DQ) typing consistent with celiac disease (DQ2 and/or DQ8)
  • Subjects must have had at least one of the following symptoms at least once per week during the month before screening: diarrhea, loose stools, abdominal pain, abdominal cramping, bloating, or gas.
  • Body weight between 35 and 120 kg

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of any severe complication of celiac disease, such as celiac disease type 1 (RCD-I) or RCD-II, enteropathy-associated T-cell lymphoma (EATL), ulcerative jejunitis, or gastrointestinal (GI) perforation
  • Diagnosis of any chronic, active GI disease other than celiac disease
  • Presence of any active infection
  • Selective immunoglobulin A (IgA) deficiency, defined as having undetectable levels of IgA
  • Known or suspected exposure to coronavirus disease 2019 (COVID-19) infection in the 4 weeks before screening
  • Administration of a within 14 days prior to randomization and the first administration of study drug
  • History or presence of any disease that, in the opinion of the Investigator, may confound the subject's participation and follow-up in the clinical trial or put the subject at unnecessary risk
  • Females who are pregnant or planning to become pregnant during the study period, or who are currently breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    PRV-015 Low Dose

    PRV-015 Low Dose, sterile solution for subcutaneous administration

    Biological: PRV-015

  • Experimental
    PRV-015 Medium Dose

    PRV-015 Medium Dose, sterile solution for subcutaneous administration

    Biological: PRV-015

  • Experimental
    PRV-015 High Dose

    PRV-015 High Dose, sterile solution for subcutaneous administration

    Biological: PRV-015

  • Placebo comparator
    Placebo

    Placebo, sterile solution for subcutaneous administration

    Other: Placebo

Interventions

  • BiologicalAMG-714Studies of AMG-714AMG-714 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fully human monoclonal antibody against interleukin 15 (IL-15)

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24

    The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. Baseline abdominal symptoms domain score was defined as the average of the daily scores for the last week of the placebo run-in period.

    Time frame: Baseline (average of Day -7 to Day -1) up to Week 24

Secondary outcomes

  1. Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24

    The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Diarrhea and loose stool domain included diarrhea and loose stool. Total score for diarrhea and loose stool domain range from 0 to 20. Higher scores indicated worse outcome. Baseline diarrhea and loose stool domain score was defined as the average of the daily scores for the last week of the placebo run-in period.

    Time frame: Baseline (average of Day -7 to Day -1) up to Week 24

  2. Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24

    The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Total GI domain included abdominal symptoms domain, diarrhea, loose stool and nausea. Total GI score range from 0 to 70. Higher scores indicated worse outcome. Baseline GI score was defined as the average of the daily scores for the last week of the placebo run-in period.

    Time frame: Baseline (average of Day -7 to Day -1) up to Week 24

  3. Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24

    The small intestinal mucosal inflammation was measured by IEL density using immunohistochemistry. Baseline was defined as IEL density from the esophagogastroduodenoscopy biopsy conducted during the run-in period.

    Time frame: Baseline to Week 24

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs included severe opportunistic infections and hypersensitivity reactions of at least moderate severity. A TEAE was defined as an AE that occurred from the first dose of post-randomization study drug administration through the end of the study.

    Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

  5. Number of Participants With Potentially Clinically Important Changes in Hematology

    Blood samples were collected to determine the hematology laboratory important changes. CHG= Change from baseline hemoglobin.

    Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

  6. Number of Participants With Potentially Clinically Important Changes in Clinical Chemistry

    Blood samples were collected to determine the clinical chemistry laboratory important changes. ULN= Upper limit of normal, mmol/L= millimoles per liter and mcmol/L= micromoles per liter.

    Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

  7. Number of Participants With Potentially Clinically Important Changes in Urinalysis

    Urine samples were collected to determine the important changes in urine. TNTC= Too numerous to count, LPF= Low power field and HPF= High power field.

    Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

  8. Number of Participants With Potentially Clinically Important Changes in Vital Signs and Body Weight

    Participant's vital signs and body weight were examined to determine the important changes. Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. mmHg= millimeters of mercury, DFB= Decrease from baseline and IFB= Increase from baseline.

    Time frame: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days

  9. Number of Participants With Anti-PRV-015 Antibodies

    Blood samples were collected to determine the presence of anti-drug antibodies by immunoassay.

    Time frame: Baseline (Day 1) and Weeks 2, 4, 12, 22, 24 and 28

  10. Minimum Serum Concentrations (Cmin) of PRV-015

    Blood samples were collected at specified timepoints to determine the Cmin.

    Time frame: Pre-dose on Day 1 and Weeks 2, 4, 8, 12, 16, 20, 22, 24 and 28

07

Results

Posted Oct 20, 2025

Participant flow

The study was conducted at 39 centers in 4 countries. A total of 648 participants were screened between 24 August 2020 and 16 January 2024, of which 255 participants were screen failures and 5 participants discontinued before run-in period. Screen failures were mainly due to not meeting eligibility criteria.

Single-blind Period (4 Weeks)
Participant flow — Single-blind Period (4 Weeks)
MilestoneSingle-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mg
Started3880000
Received treatment3870000
Completed3520000
Not completed360000
Withdrew: Not treated10000
Withdrew: Run-in failure270000
Withdrew: Withdrawal by subject70000
Withdrew: Investigator or sponsor judgement10000
Double-blind Period (24 Weeks)
Participant flow — Double-blind Period (24 Weeks)
MilestoneSingle-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mg
Started057565756
Received treatment057565754
Completed051475149
Not completed06967
Withdrew: Lost to follow-up01100
Withdrew: Withdrawal by subject03556
Withdrew: Investigator or sponsor judgement01001
Withdrew: Other01310

Outcome measures

PrimaryAbsolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24

The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Abdominal Symptoms domain included abdominal cramping, abdominal pain, bloating and gas. Total score for abdominal symptoms domain range from 0 to 40. Higher scores indicated worse outcome. Baseline abdominal symptoms domain score was defined as the average of the daily scores for the last week of the placebo run-in period.

Time frame:
Baseline (average of Day -7 to Day -1) up to Week 24
Reported as:
Least squares mean · score on a scale
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24
score on a scalePlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Abdominal Symptoms Domain Score Through Week 24-1.32 (-1.66 to -0.98)-1.28 (-1.62 to -0.94)-1.21 (-1.55 to -0.88)-1.28 (-1.63 to -0.93)
Statistical analysis
  • Placebo vs PRV-015 100 mg · MMRM · p = 0.8543 · Least square (ls) mean difference: 0.04 · 95% CI -0.43 to 0.52
  • Placebo vs PRV-015 300 mg · MMRM · p = 0.6552 · Ls mean difference: 0.11 · 95% CI -0.37 to 0.59
  • Placebo vs PRV-015 600 mg · MMRM · p = 0.8705 · Ls mean difference: 0.04 · 95% CI -0.45 to 0.53
SecondaryAbsolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24

The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Diarrhea and loose stool domain included diarrhea and loose stool. Total score for diarrhea and loose stool domain range from 0 to 20. Higher scores indicated worse outcome. Baseline diarrhea and loose stool domain score was defined as the average of the daily scores for the last week of the placebo run-in period.

Time frame:
Baseline (average of Day -7 to Day -1) up to Week 24
Reported as:
Least squares mean · score on a scale
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24
score on a scalePlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Diarrhea and Loose Stool Domain Score Through Week 24-0.77 (-1.15 to -0.40)-0.66 (-1.04 to -0.28)-1.02 (-1.39 to -0.64)-1.07 (-1.46 to -0.68)
Statistical analysis
  • Placebo vs PRV-015 100 mg · MMRM · p = 0.6757 · Ls mean difference: 0.11 · 95% CI -0.42 to 0.65
  • Placebo vs PRV-015 300 mg · MMRM · p = 0.3645 · Ls mean difference: -0.25 · 95% CI -0.78 to 0.29
  • Placebo vs PRV-015 600 mg · MMRM · p = 0.2791 · Ls mean difference: -0.30 · 95% CI -0.84 to 0.24
SecondaryAbsolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24

The CeD PRO questionnaire was captured daily in the eDiary. The questionnaire included 9 items: abdominal cramping, abdominal pain, bloating, gas, diarrhea, loose stool, nausea, headache and tiredness. Participants were asked to rate their symptom severity on an 11-point scale and scores range from 0 (not experiencing the symptom) to 10 (the worst possible symptom experience). Total GI domain included abdominal symptoms domain, diarrhea, loose stool and nausea. Total GI score range from 0 to 70. Higher scores indicated worse outcome. Baseline GI score was defined as the average of the daily scores for the last week of the placebo run-in period.

Time frame:
Baseline (average of Day -7 to Day -1) up to Week 24
Reported as:
Least squares mean · score on a scale
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24
score on a scalePlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Absolute Change From Baseline in Celiac Disease Patient-Reported Outcome Total Gastrointestinal (GI) Score Through Week 24-0.89 (-1.15 to -0.63)-0.84 (-1.10 to -0.57)-0.88 (-1.14 to -0.62)-1.05 (-1.32 to -0.78)
Statistical analysis
  • Placebo vs PRV-015 100 mg · MMRM · p = 0.7829 · Ls mean difference: 0.05 · 95% CI -0.32 to 0.42
  • Placebo vs PRV-015 300 mg · MMRM · p = 0.9503 · Ls mean difference: 0.01 · 95% CI -0.36 to 0.38
  • Placebo vs PRV-015 600 mg · MMRM · p = 0.4107 · Ls mean difference: -0.16 · 95% CI -0.54 to 0.22
SecondaryAbsolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24

The small intestinal mucosal inflammation was measured by IEL density using immunohistochemistry. Baseline was defined as IEL density from the esophagogastroduodenoscopy biopsy conducted during the run-in period.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · cells/100 epithelial cells
Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24
cells/100 epithelial cellsPlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Absolute Change From Baseline in Intraepithelial Lymphocyte (IEL) Density at Week 24-0.39 (-3.82 to 3.03)1.54 (-1.99 to 5.07)-4.11 (-7.56 to -0.66)-4.53 (-8.13 to -0.93)
Statistical analysis
  • Placebo vs PRV-015 100 mg · ANCOVA · p = 0.4397 · Ls mean difference: 1.94 · 95% CI -3.00 to 6.87
  • Placebo vs PRV-015 300 mg · ANCOVA · p = 0.1337 · Ls mean difference: -3.72 · 95% CI -8.58 to 1.15
  • Placebo vs PRV-015 600 mg · ANCOVA · p = 0.1021 · Ls mean difference: -4.14 · 95% CI -9.11 to 0.83
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs included severe opportunistic infections and hypersensitivity reactions of at least moderate severity. A TEAE was defined as an AE that occurred from the first dose of post-randomization study drug administration through the end of the study.

Time frame:
From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)
ParticipantsPlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Any TEAE34343629
TEAE leading to study treatment discontinuation1120
Treatment-emergent SAE1001
Treatment-emergent AESI2111
SecondaryNumber of Participants With Potentially Clinically Important Changes in Hematology

Blood samples were collected to determine the hematology laboratory important changes. CHG= Change from baseline hemoglobin.

Time frame:
From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Important Changes in Hematology
ParticipantsPlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Hemoglobin: CHG <=-20 g/L0012
Neutrophils: <1 10^9/L2142
SecondaryNumber of Participants With Potentially Clinically Important Changes in Clinical Chemistry

Blood samples were collected to determine the clinical chemistry laboratory important changes. ULN= Upper limit of normal, mmol/L= millimoles per liter and mcmol/L= micromoles per liter.

Time frame:
From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Important Changes in Clinical Chemistry
ParticipantsPlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Alanine Aminotransferase: >=3x ULN1412
Aspartate Aminotransferase: >=3x ULN1200
Chloride: >125 mmol/L1010
Creatinine: >=132 mcmol/L1100
Potassium: >6 mmol/L0021
Sodium: <125 mmol/L0010
SecondaryNumber of Participants With Potentially Clinically Important Changes in Urinalysis

Urine samples were collected to determine the important changes in urine. TNTC= Too numerous to count, LPF= Low power field and HPF= High power field.

Time frame:
From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Important Changes in Urinalysis
ParticipantsPlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Bacteria: Present54515547
Crystals: Present3425
Erythrocytes (/HPF): Many/TNTC1043
Glucose: 3+/4+1210
Hyaline Casts (/HPF): Few/Moderate/Many3230
Hyaline Casts (/LPF): Few/Moderate/Many—11—
Ketones: 3+1231
Leukocyte Esterase: 3+/4+19121615
Leukocytes (/HPF): Many/TNTC11397
Nitrite: Positive2121
Squamous Epithelial Cells (/HPF): Many/TNTC6068
SecondaryNumber of Participants With Potentially Clinically Important Changes in Vital Signs and Body Weight

Participant's vital signs and body weight were examined to determine the important changes. Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. mmHg= millimeters of mercury, DFB= Decrease from baseline and IFB= Increase from baseline.

Time frame:
From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Important Changes in Vital Signs and Body Weight
ParticipantsPlaceboPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
SBP: <=95 mmHg and DFB >=20 mmHg5261
SBP: >=160 mmHg and IFB >=20 mmHg2101
DBP: >=110 mmHg and IFB >=10 mmHg0001
Heart Rate: <=50 bpm and DFB >=20 bpm1110
Heart Rate: >=120 bpm and IFB >=20 bpm0001
Body weight: >=5% DFB81197
Body weight: >=5% IFB98135
SecondaryNumber of Participants With Anti-PRV-015 Antibodies

Blood samples were collected to determine the presence of anti-drug antibodies by immunoassay.

Time frame:
Baseline (Day 1) and Weeks 2, 4, 12, 22, 24 and 28
Reported as:
Count of participants · Participants
Number of Participants With Anti-PRV-015 Antibodies
ParticipantsPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Baseline387
Week 2899
Week 4565
Week 12454
Week 22442
Week 24432
Week 28432
SecondaryMinimum Serum Concentrations (Cmin) of PRV-015

Blood samples were collected at specified timepoints to determine the Cmin.

Time frame:
Pre-dose on Day 1 and Weeks 2, 4, 8, 12, 16, 20, 22, 24 and 28
Reported as:
Geometric mean · nanogram per milliliter
Minimum Serum Concentrations (Cmin) of PRV-015
nanogram per milliliterPRV-015 100 mgPRV-015 300 mgPRV-015 600 mg
Week 28778 ± 74.127820 ± 39.866400 ± 46.1
Week 415140 ± 42.851190 ± 42.198420 ± 49.4
Week 821790 ± 46.461990 ± 66.5142600 ± 43.7
Week 1223630 ± 46.873150 ± 56.5168300 ± 37.9
Week 1622960 ± 46.775830 ± 65.1166700 ± 44.9
Week 2027000 ± 42.574110 ± 67.8186400 ± 51.2
Week 2225410 ± 36.273120 ± 64.2181000 ± 55.6
Week 2426680 ± 40.372400 ± 49.6160500 ± 47.5
Week 2810210 ± 58.032810 ± 80.069370 ± 78.3

Adverse events

Collected over Single-blind Period: From first dose of study drug administration (Day 1) up to 28 days. Double-blind Period: From first dose of study drug administration (Day 1) up to 28 days after the last dose administration, 197 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single-blind: Placebo0/387 (0%)2/387 (0.5%)0/387 (0%)
Double-blind: Placebo0/57 (0%)1/57 (1.8%)22/57 (38.6%)
Double-blind: PRV-015 100 mg0/56 (0%)0/56 (0%)18/56 (32.1%)
Double-blind: PRV-015 300 mg0/57 (0%)0/57 (0%)22/57 (38.6%)
Double-blind: PRV-015 600 mg0/54 (0%)1/54 (1.9%)19/54 (35.2%)
Most frequent serious events
Most frequent serious events
EventSingle-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mg
PresyncopeNervous system disorders0/3870/570/560/571/54
Pelvic FractureInjury, poisoning and procedural complications0/3871/570/560/570/54
Gluten SensitivityMetabolism and nutrition disorders1/3870/570/560/570/54
IntussusceptionGastrointestinal disorders1/3870/570/560/570/54
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSingle-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mg
Covid-19Infections and infestations0/3873/575/568/575/54
DiarrhoeaGastrointestinal disorders0/3876/571/564/574/54
Upper Respiratory Tract InfectionInfections and infestations0/3875/573/564/574/54
HeadacheNervous system disorders0/3871/574/565/572/54
NauseaGastrointestinal disorders0/3871/572/565/573/54
Abdominal PainGastrointestinal disorders0/3873/573/560/574/54
MigraineNervous system disorders0/3874/572/561/571/54
RashSkin and subcutaneous tissue disorders0/3874/570/563/571/54
Injection Site BruisingGeneral disorders0/3870/570/562/573/54
Injection Site ReactionGeneral disorders0/3871/573/563/573/54

Baseline characteristics

Single-blind period: Participants treated with single-blind placebo in run-in period are included. Double-blind period: The intent-to-treat analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Single-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mgTotal
Single-blind period41.2 ± 13.8————41.2 ± 13.8
Double-blind period—41.0 ± 14.5341.9 ± 14.8239.0 ± 12.2537.9 ± 12.5839.9 ± 13.59
Sex: Female, Male
Sex: Female, Male(Participants)Single-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mgTotal
Single-blind period — Female3130000313
Single-blind period — Male74000074
Double-blind period — Female053385045186
Double-blind period — Male041871140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mgTotal
Single-blind period — Black or African American4————4
Single-blind period — White375————375
Single-blind period — Asian1————1
Single-blind period — American Indian or Alaska Native2————2
Single-blind period — Not Reported3————3
Single-blind period — Unknown1————1
Single-blind period — Multiple1————1
Double-blind period — Black or African American—01001
Double-blind period — White—57555653221
Double-blind period — Asian—00000
Double-blind period — American Indian or Alaska Native—00000
Double-blind period — Not Reported—00022
Double-blind period — Unknown—00011
Double-blind period — Multiple—00101
Celiac Disease Patient Reported Outcome (CeD PRO) Abdominal Symptoms Domain Score
Celiac Disease Patient Reported Outcome (CeD PRO) Abdominal Symptoms Domain Score(Participants)Single-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mgTotal
Single-blind period — Score: <3—————0
Single-blind period — Score: >=3—————0
Double-blind period — Score: <3—1313131352
Double-blind period — Score: >=3—44434443174
Number of Participants for Stratification Factor Villous Height-to-Crypt Depth Ratio (VH:CD)
Number of Participants for Stratification Factor Villous Height-to-Crypt Depth Ratio (VH:CD)(Participants)Single-blind: PlaceboDouble-blind: PlaceboDouble-blind: PRV-015 100 mgDouble-blind: PRV-015 300 mgDouble-blind: PRV-015 600 mgTotal
Single-blind period — Ratio: <2—————0
Single-blind period — Ratio: >=2—————0
Double-blind period — Ratio: <2—37373736147
Double-blind period — Ratio: >=2—2019202079
08

Study locations

38 sites
  • Clinical Site
    Los Angeles, California 90036, United States
  • Clinical Site
    Ventura, California 93003, United States
  • Clinical Site
    Denver, Colorado 80209, United States
  • Clinical Site
    Leesburg, Florida 34748, United States
  • Clinical Site
    Tampa, Florida 33613, United States
  • Clinical Site
    Winter Park, Florida 32789, United States
  • Clinical Site
    Chicago, Illinois 60637, United States
  • Clinical Trial Site
    Northbrook, Illinois 60062, United States
  • Clinical Trial Site
    Chevy Chase, Maryland 20815, United States
  • Clinical Site
    Boston, Massachusetts 02111, United States
  • Clinical Site
    Chesterfield, Michigan 48047, United States
  • Clinical Site
    Rochester, Minnesota 55905, United States
  • Clinical Site
    Morristown, New Jersey 07960, United States
  • Clinical Trial Site
    Brooklyn, New York 11235, United States
  • Clinical Site
    New Windsor, New York 12553, United States
  • Clinical Trial Site
    New York, New York 10032, United States
  • Clinical Site
    Raleigh, North Carolina 27607, United States
  • Clinical Trial Site
    Dublin, Ohio 43016, United States
  • Clinical Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Site
    Uniontown, Pennsylvania 14401, United States
  • Clinical Site
    Warwick, Rhode Island 02886, United States
  • Clinical Trial Site
    North Charleston, South Carolina 29405, United States
  • Clinical Site
    Nashville, Tennessee 37212, United States
  • Clinical Trial Site
    Cedar Park, Texas 78613, United States
  • Clinical Site
    Garland, Texas 75044, United States
  • Clinical Site
    West Jordan, Utah 84088, United States
  • Clinical Site
    Bellevue, Washington 98004, United States
  • Clinical Site
    Tacoma, Washington 98405, United States
  • Clinical Site
    Hamilton, Ontario L8S4K1, Canada
  • Clinical Site
    Amsterdam, 1105 AZ, Netherlands
  • Clinical Site
    Seville, Andalusia 41013, Spain
  • Clinical Site
    León, Castille and León 24071, Spain
  • Clinical Trial Site
    Terrassa, Catalonia 082211, Spain
  • Clinical Trial Site
    Girona, 17007, Spain
  • Clinical Trial Site
    Lleida, 25196, Spain
  • Clinical Site
    Madrid, 28034, Spain
  • Clinical Site
    Madrid, 28041, Spain
  • Clinical Site
    Madrid, 28222, Spain
09

References and documents

Publications

  • Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2. PubMed 41039829 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2024, 47 months.

Results were first posted in Oct 2025, 1 year 2 months after primary completion.

Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
Jun 11, 2020
StartActual
Aug 24, 2020
Primary completionActual
Jul 30, 2024
CompletionActual
Jul 30, 2024
Results first posted
Oct 20, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04424927
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Aug 24, 2020
Primary completion
Jul 30, 2024
Completion
Jul 30, 2024
Results posted
Oct 20, 2025
Last update
Oct 20, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AMG-714

Start the discussion